We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.174%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Mon, 15th Jun 2020 15:52

Tuesday 16 June
Marshall Motor
Clearstar
Epwin Group
Coca-Cola HBC
Science Group
Altus Strategies
Arbuthnot Banking
Evraz
Andrews Sykes Group
FDM Group
Wednesday 17 June
Amigo Holdings (re board removal)
RTC Group 
Wentworth Resources 
STM Group
Salt Lake Potash
Domino's Pizza Group
Pelatro 
UK Oil & Gas
G4S
Thursday 18 June
Ted Baker (re share placing)
IP Group
Horizon Discovery
Ten Entertainment
Shield Therapeutics
Tremor International
Jadestone Energy
Vietnam Enterprise
Intelligent Ultrasound Group
Block Energy
RBG Holdings
Impact Healthcare
Michelmersh
Immupharma
Friday 19 June
boohoo
Power Metal Resources
Costain Group
Learning Technologies Group
John Wood Group
Trinty Exploration
AA
Monday 22 June
Ethernity Networks 
SAGA 
Wincanton
Avacta
President Energy
 
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

Read more
24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
22 Feb 2021 11:01

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Read more
22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Read more
22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

Read more
22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Read more
18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Read more
18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

Read more
16 Feb 2021 11:31

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Read more
16 Feb 2021 09:48

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Read more
16 Feb 2021 09:38

Avacta upbeat on initial data for Covid-19 rapid test study

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.

Read more
8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

Read more
8 Feb 2021 10:46

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Read more
8 Feb 2021 09:37

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.